Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia.
In the present study, we investigated the roles of TGF-β signaling pathway in a rat benign prostatic hyperplasia (BPH) model treated with cetrorelix. TGF-β1 and c-Myc expression were measured by qRT-PCR and Western blotting in the proximal and distal region of ventral prostatic lobes, respectively. We observed that treatment with cetrorelix led to a significant reduction of ventral prostate weight in a dose-dependent manner. In the proximal region, after cetrorelix treatment, the expression of TGF-β1 was dramatically increased (P<0.05), while the expression of c-Myc was significantly decreased (P<0.05). In comparison with the control group, the cetrorelix groups had more TUNEL-positive cells. Our findings strongly suggest that the TGF-β signaling pathway may be one of the major causes responsible for prostate volume reduction in BPH rats after cetrorelix treatment.
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Dong
D
Yang
Department of Urology, Shenzhen People's Hospital, Second Clinical Medical College, Jinan University, Shenzhen, 518020, China.
Teng
T
Hou
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Xiong
X
Yang
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yan
Y
Ma
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Longwang
L
Wang
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. bingli@mail.hust.edu.cn.
Bing
B
Li
D000818:Animals; D001284:Atrophy / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors*; D006727:Hormone Antagonists; D006801:Humans; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011470:Prostatic Hyperplasia / Q000139:chemically induced / Q000473:pathology* / Q000503:physiopathology*; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D053773:Transforming Growth Factor beta1 / Q000378:metabolism*
D006727:Hormone Antagonists; D016271:Proto-Oncogene Proteins c-myc; D053773:Transforming Growth Factor beta1; D007987:Gonadotropin-Releasing Hormone; C062876:cetrorelix